# US 2013/0259847 A1 · Interrogatory cell-based assays and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0259847 A1
- Document ID: US20130259847A1
- Status: Published application
- Kind: A1
- Application number: 13/607,587
- Filed: 2012-09-07
- Published: 2013-10-03
- Earliest claimed: 2012-04-02
- Assignees: Berg Pharma LLC
- Inventors: Vivek K. Vishnudas; Rangaprasad Sarangarajan; Niven Rajin Narain; Min Du; Tony Walshe
- Web page: https://patentgrep.com/patent/US20130259847A1

## CPC

- G16B 5/00: ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C12Q 1/025: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics (antimicrobial activity C12Q1/18)}
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Described herein is a discovery Platform Technology for analyzing a biological system or process (e.g., a disease condition, such as cancer) via model building

## Claims

### Claim 1

A method for identifying a modulator of a biological system, the method comprising:
establishing a model for the biological system, using cells associated with the biological system, to represents a characteristic aspect of the biological system;
obtaining a first data set from the model, wherein the first data set represents global proteomic changes in the cells associated with the biological system;
obtaining a second data set from the model, wherein the second data set represents one or more functional activities or cellular responses of the cells associated with the biological system, wherein said one or more functional activities or cellular responses of the cells comprises global enzymatic activity and/or an effect of the global enzyme activity on the enzyme metabolites or substrates in the cells associated with the biological system;
generating a consensus causal relationship network among the global proteomic changes and the one or more functional activities or cellular responses based solely on the first and second data sets using a programmed computing device, wherein the generation of the consensus causal relationship network is not based on any known biological relationships other than the first and second data sets; and
identifying, from the consensus causal relationship network, a causal relationship unique in the biological system, wherein at least one enzyme associated with the unique causal relationship is identified as a modulator of the biological system.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first data set further represents lipidomic data characterizing the cells associated with the biological system.

### Claim 3 (depends on 2)

The method of claim 2, wherein the consensus causal relationship network is generated among the global proteomic changes, lipidomic data, and the one or more functional activities or cellular responses of the cells, wherein said one or more functional activities or cellular responses of the cells comprises global enzymatic activity and/or the effect of the global enzymatic activity on at least one enzyme metabolite or substrate.

### Claim 4 (depends on 1)

The method of claim 1, wherein the first data set further represents one or more of lipidomic, metabolomic, transcriptomic, genomic and SNP data characterizing the cells associated with the biological system.

### Claim 5

(canceled)

### Claim 6 (depends on 4)

The method of claim 4, wherein the consensus causal relationship network is generated among the global proteomic changes, the one or more of lipidomic, metabolomic, transcriptomic, genomic, and SNP data, and the one or more functional activities or cellular responses of the cells, wherein said one or more functional activities or cellular responses of the cells comprises global enzymatic activity and/or the effect of the global enzymatic activity on at least one enzyme metabolite or substrate.

### Claim 7 (depends on 1)

The method of claim 1, wherein the global enzyme activity comprises global kinase activity.

### Claim 8 (depends on 1)

The method of claim 1, wherein the effect of the global enzyme activity on the enzyme metabolites or substrates comprises the phospho proteome of the cells.

### Claim 9 (depends on 1)

The method of claim 1, wherein the second data set representing one or more functional activities or cellular responses of the cell further comprises one or more of bioenergetics, cell proliferation, apoptosis, organellar function, cell migration, tube formation, chemotaxis, extracellular matrix degradation, sprouting, and a genotype-phenotype associate actualized by functional models selected from ATP, ROS, OXPHOS, and Seahorse assays.

### Claim 10 (depends on 4)

The method of claim 4, wherein the consensus causal relationship network is generated among the global proteomic changes, the one or more of lipidomic, metabolomic, transcriptomic, genomic, and SNP data, and the one or more functional activities or cellular responses of the cells, wherein said one or more functional activities or cellular responses of the cells comprises global enzymatic activity and/or the effect of the global enzymatic activity on at least one enzyme metabolite or substrate and further comprises one or more of bioenergetics, cell proliferation, apoptosis, organellar function, cell migration, tube formation, chemotaxis, extracellular matrix degradation, sprouting, and a genotype-phenotype associate actualized by functional models selected from ATP, ROS, OXPHOS, and Seahorse assays.

### Claim 11 (depends on 1)

The method of claim 1, wherein the model of the biological system comprises an in vitro culture of cells associated with the biological system, optionally further comprising a matching in vitro culture of control cells.

### Claim 12 (depends on 11)

The method of claim 11, wherein the in vitro culture of the cells is subject to an environmental perturbation, and the in vitro culture of the matching control cells is identical cells not subject to the environmental perturbation.

### Claim 13 (depends on 12)

The method of claim 12, wherein the environmental perturbation comprises one or more of contact with a bioactive agent, a change in culture condition, introduction of a genetic modification/mutation, and introduction of a vehicle that causes a genetic modification/mutation.

### Claim 14 (depends on 12)

The method of claim 12, wherein the environmental perturbation comprises contacting the cells with an enzymatic activity inhibitor.

### Claim 15 (depends on 14)

The method of claim 14, wherein the enzymatic activity inhibitor is a kinase inhibitor.

### Claim at position 16

16-17. (canceled)

### Claim 18 (depends on 1)

The method of claim 1, wherein the generating step is carried out by an artificial intelligence (AI)-based informatics platform.

### Claim 19 (depends on 18)

The method of claim 18, wherein the AI-based informatics platform receives all data input from the first and second data sets without applying a statistical cut-off point.

### Claim 20 (depends on 1)

The method of claim 1, wherein the consensus causal relationship network established in the generating step is further refined to a simulation causal relationship network, before the identifying step, by in silico simulation based on input data, to provide a confidence level of prediction for one or more causal relationships within the consensus causal relationship network.

### Claim at position 20

21-24. (canceled)

### Claim 25 (depends on 1)

The method of claim 1, wherein the biological system is a disease process, and the method comprises establishing a model for the disease process, using disease related cells, to represents a characteristic aspect of the disease process; and
identifying, from the consensus causal relationship network, a causal relationship unique in the disease process, wherein at least one enzyme associated with the unique causal relationship is identified as a modulator of the disease process.

### Claim at position 22

26-33. (canceled)

### Claim 34 (depends on 25)

The method of claim 25, wherein the disease process is cancer, diabetes, obesity, cardiovascular disease, age related macular degeneration, diabetic retinopathy, or inflammatory disease.

### Claim 35 (depends on 25)

The method of claim 25, wherein the disease process comprises angiogenesis.

### Claim at position 25

36-42. (canceled)

### Claim 43 (depends on 25)

The method of claim 25, wherein the characteristic aspect of the disease process comprises a hypoxia condition, a hyperglycemic condition, a lactic acid rich culture condition, or combinations thereof.

### Claim at position 27

44-48. (canceled)

### Claim 49

A method for identifying a modulator of a biological system, the method comprising:
establishing a model for the biological system, using cells associated with the biological system, to represents a characteristic aspect of the biological system;
obtaining a first data set from the model, wherein the first data set represents global proteomic changes in the cells and one or more of lipidomic, metabolomic, transcriptomic, genomic, and SNP data characterizing the cells associated with the biological system;
obtaining a second data set from the model, wherein the second data set represents one or more functional activities or cellular responses of the cells associated with the biological system, wherein said one or more functional activities or cellular responses of the cells comprises global kinase activity and/or an effect of the global kinase activity on the kinase metabolites or substrates in the cells associated with the biological system;
generating a consensus causal relationship network among the global proteomic changes, the one or more of lipidomic, metabolomic, transcriptomic, genomic, and SNP data, and the one or more functional activities or cellular responses based solely on the first and second data sets using a programmed computing device, wherein the generation of the consensus causal relationship network is not based on any known biological relationships other than the first and second data sets; and
identifying, from the consensus causal relationship network, a causal relationship unique in the biological system, wherein at least one kinase associated with the unique causal relationship is identified as a modulator of the biological system.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

A method for treating, alleviating a symptom of, inhibiting progression of, preventing, diagnosing, or prognosing a disease in a mammalian subject, the method comprising:
administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a biologically active substance that affects the modulator identified by any one of claims 1-48, thereby treating, alleviating a symptom of, inhibiting progression of, preventing, diagnosing, or prognosing the disease.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

A method of diagnosing or prognosing a disease in a mammalian subject, the method comprising:
determining an expression or activity level, in a biological sample obtained from the subject, of one or more modulators identified by any one of claims 1-48; and
comparing the level in the subject with the level of expression or activity of the one or more modulators in a control sample,
wherein a difference between the level in the subject and the level of expression or activity of the one or more modulators in the control sample is an indication that the subject is afflicted with a disease, or predisposed to developing a disease, or responding favorably to a therapy for a disease, thereby diagnosing or prognosing the disease in the mammalian subject.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

A method of identifying a therapeutic compound for treating, alleviating a symptom of, inhibiting progression of, or preventing a disease in a mammalian subject, the method comprising:
contacting a biological sample from a mammalian subject with a test compound;
determining the level of expression, in the biological sample, of one or more modulators identified by any one of claims 1-48;
comparing the level of expression of the one or more modulators in the biological sample with a control sample not contacted by the test compound; and
selecting the test compound that modulates the level of expression of the one or more modulators in the biological sample,
thereby identifying a therapeutic compound for treating, alleviating a symptom of, inhibiting progression of, or preventing a disease in a mammalian subject.

### Claim at position 32

53-55. (canceled)

### Claim 56

A method of diagnosing or prognosing a disease in a mammalian subject, the method comprising:
determining an expression or activity level, in a biological sample obtained from the subject, of any one or more proteins of TCOF1, TOP2A, CAMK2A, CDK1, CLTCL1, EIF4G1, ENO1, FBL, GSK3B, HDLBP, HIST1H2BA, HMGB2, HNRNPK, HNRPDL, HSPA9, MAP2K2, LDHA, MAP4, MAPK1, MARCKS, NME1, NME2, PGK1, PGK2, RAB7A, RPL17, RPL28, RPS5, RPS6, SLTM, TMED4, TNRCBA, TUBB, and UBE21; and
comparing the level in the subject with the level of expression or activity of the one or more proteins in a control sample,
wherein a difference between the level in the subject and the level of expression or activity of the one or more proteins in the control sample is an indication that the subject is afflicted with a disease, or predisposed to developing a disease, or responding favorably to a therapy for a disease, thereby diagnosing or prognosing the disease in the mammalian subject.

### Claim 57

(canceled)

### Claim 58

A method of identifying a therapeutic compound for treating, alleviating a symptom of, inhibiting progression of, or preventing a disease in a mammalian subject, the method comprising:
contacting a cell with a test compound;
determining the level of expression, in the biological sample, of any one or more proteins of TCOF1, TOP2A, CAMK2A, CDK1, CLTCL1, EIF4G1, ENO1, FBL, GSK3B, HDLBP, HIST1H2BA, HMGB2, HNRNPK, HNRPDL, HSPA9, MAP2K2, LDHA, MAP4, MAPK1, MARCKS, NME1, NME2, PGK1, PGK2, RAB7A, RPL17, RPL28, RPS5, RPS6, SLTM, TMED4, TNRCBA, TUBB, and UBE21;
comparing the level of expression of the one or more proteins in the cell with a control cell not contacted by the test compound; and
selecting the test compound that modulates the level of expression of the one or more proteins in the cell,
thereby identifying a therapeutic compound for treating, alleviating a symptom of, inhibiting progression of, or preventing a disease in a mammalian subject.

### Claim at position 36

59-60. (canceled)

### Claim 61

A method for identifying a modulator of angiogenesis, said method comprising:
(1) establishing a model for angiogenesis, using cells associated with angiogenesis, to represents a characteristic aspect of angiogenesis;
(2) obtaining a first data set from the model for angiogenesis, wherein the first data set represents one or more of genomic data, lipidomic data, proteomic data, metabolomic data, transcriptomic data, and single nucleotide polymorphism (SNP) data characterizing the cells associated with angiogenesis;
(3) obtaining a second data set from the model for angiogenesis, wherein the second data set represents one or more functional activities or cellular responses of the cells associated with angiogenesis;
(4) generating a consensus causal relationship network among the one or more of genomic data, lipidomic data, proteomic data, metabolic data, transcriptomic data, and single nucleotide polymorphism (SNP) data characterizing the cells associated with angiogenesis, and the one or more functional activities or cellular responses of the cells associated with angiogenesis based solely on the first data set and the second data set using a programmed computing device, wherein the generation of the consensus causal relationship network is not based on any known biological relationships other than the first data set and the second data set;
(5) identifying, from the consensus causal relationship network, a causal relationship unique in angiogenesis, wherein a gene, lipid, protein, metabolite, transcript, or SNP associated with the unique causal relationship is identified as a modulator of angiogenesis.

### Claim 62 (depends on 61)

The method of claim 61, wherein the first data set represents lipidomic data; and wherein the method comprises
(1) generating a consensus causal relationship network among the lipidomics data and the one or more functional activities or cellular responses based solely on the first data set and the second data set using a programmed computing device, wherein the generation of the consensus causal relationship network is not based on any known biological relationships other than the first data set and the second data set;
(2) identifying, from the consensus causal relationship network, a causal relationship unique in angiogenesis, wherein a lipid associated with the unique causal relationship is identified as a modulator of angiogenesis.

### Claim 63 (depends on 61)

The method of claim 61, wherein the second data set representing one or more functional activities or cellular responses of the cells associated with angiogenesis comprises global enzymatic activity and/or an effect of the global enzymatic activity on the enzyme metabolites or substrates in the cells associated with angiogenesis, and wherein the method comprises
(1) generating a consensus causal relationship network among the lipidomics data and the one or more functional activities or cellular responses based solely on the first data set and the second data set using a programmed computing device, wherein the generation of the consensus causal relationship network is not based on any known biological relationships other than the first data set and the second data set;
(2) identifying, from the consensus causal relationship network, a causal relationship unique in angiogenesis, wherein a lipid associated with the unique causal relationship is identified as a modulator of angiogenesis.

### Claim 64

(canceled)

### Claim 65 (depends on 63)

The method of claim 63, wherein the global enzyme activity comprises global kinase activity and an effect of the global enzymatic activity on the enzyme metabolites or substrates in the cells associated with angiogenesis comprises the phosphoproteome of the cell.

### Claim at position 42

66-68. (canceled)

### Claim 69 (depends on 61)

The method of claim 61, wherein the model for angiogenesis comprising cells associated with angiogenesis is selected from the group consisting of an in vitro cell culture angiogenesis model, rat aorta microvessel model, newborn mouse retina model, chick chorioallantoic membrane (CAM) model, corneal angiogenic growth factor pocket model, subcutaneous sponge angiogenic growth factor implantation model, MATRIGEL® angiogenic growth factor implantation model, and tumor implanation model; and wherein the model of angiogenesis optionally further comprises a matching control model of angiogenesis comprising control cells.

### Claim at position 44

70-72. (canceled)

### Claim 73 (depends on 69)

The method of claim 69, wherein the cells in the model of angiogenesis are subject to an environmental perturbation, and the cells in the matching model of angiogenesis are identical cells not subject to the environmental perturbation.

### Claim 74 (depends on 73)

The method of claim 73, wherein the environmental perturbation comprises one or more of a contact with an agent, a change in culture condition, an introduced genetic modification or mutation, a vehicle that causes a genetic modification or mutation, induction of ischemia, a pro-angiogenic agent, and an anti-angiogenic agent.

### Claim at position 47

75-82. (canceled)

### Claim 83 (depends on 61)

The method of claim 61, wherein the second data set representing one or more functional activities or a cellular responses of the cells associated with angiogenesis comprises one or more of bioenergetics, cell proliferation, apoptosis, organellar function, cell migration, tube formation, enzyme activity, chemotaxis, extracellular matrix degradation, sprouting, and a genotype-phenotype association actualized by functional models selected from ATP, ROS, OXPHOS, and Seahorse assays.

### Claim at position 49

84-85. (canceled)

### Claim 86 (depends on 61)

The method of claim 61, wherein step (4) is carried out by an artificial intelligence (AI)-based informatics platform.

### Claim 87

(canceled)

### Claim 88 (depends on 86)

The method of claim 86, wherein the AI-based informatics platform receives all data input from the first data set and the second data set without applying a statistical cut-off point.

### Claim 89 (depends on 61)

The method of claim 61, wherein the consensus causal relationship network established in step (4) is further refined to a simulation causal relationship network, before step (5), by in silico simulation based on input data, to provide a confidence level of prediction for one or more causal relationships within the consensus causal relationship network.

### Claim 90 (depends on 61)

The method of claim 61, wherein the unique causal relationship is identified as part of a differential causal relationship network that is uniquely present in cells, and absent in the matching control cells.

### Claim 91 (depends on 61)

The method of claim 61, wherein the unique causal relationship identified is a relationship between at least one pair selected from the group consisting of expression of a gene and level of a lipid; expression of a gene and level of a transcript; expression of a gene and level of a metabolite; expression of a first gene and expression of a second gene; expression of a gene and presence of a SNP; expression of a gene and a functional activity; level of a lipid and level of a transcript; level of a lipid and level of a metabolite; level of a first lipid and level of a second lipid; level of a lipid and presence of a SNP; level of a lipid and a functional activity; level of a first transcript and level of a second transcript; level of a transcript and level of a metabolite; level of a transcript and presence of a SNP; level of a first transcript and level of a functional activity; level of a first metabolite and level of a second metabolite; level of a metabolite and presence of a SNP; level of a metabolite and a functional activity; presence of a first SNP and presence of a second SNP; and presence of a SNP and a functional activity.

### Claim 92 (depends on 91)

The method of claim 91, wherein the functional activity is selected from the group consisting of bioenergetics, cell proliferation, apoptosis, organellar function, cell migration, tube formation, enzyme activity, chemotaxis, extracellular matrix degradation, and sprouting, and a genotype-phenotype association actualized by functional models selected from ATP, ROS, OXPHOS, and Seahorse assays.

### Claim at position 57

93-94. (canceled)

### Claim 95 (depends on 61)

The method of claim 61, wherein the unique causal relationship identified is a relationship between at least a level of a lipid, expression of a gene, and one or more functional activities wherein the functional activity is a kinase activity.

### Claim at position 59

96-111. (canceled)
